astrazeneca

Olaparib Phase 3 Development Discontinued by AstraZeneca

(January 1, 2012) In a surprise announcement, AstraZeneca put out a press release in late December announcing the cancellation Phase 3 development for olaparib. The official reason given for abandoning development was as follows: “The decision to discontinue olaparib’s development in serous ovarian cancer was made following a review of an interim analysis of a …

Olaparib Phase 3 Development Discontinued by AstraZenecaRead More »

AstraZeneca’s Foray into Parp Inhibitors Started in 2006

AstraZeneca stands to benefit greatly from the successful studies, to date, on the use of Parp Inhibitors in the treatment of cancer. The targeted treatment received mass publicity in June 2009 when a study came out showed great promise and results. So how did AstraZeneca become involved with parp inhibitors? In 2006, AstraZeneca acquired a …

AstraZeneca’s Foray into Parp Inhibitors Started in 2006Read More »